AbbVie M14-239

About this trial

The primary objective is to determine the overall response rate (ORR) of Teliso-V in subjects with c-Met-positive (c-Met+) NSCLC.

Patient Profile

Subjects with locally advanced or metastatic NSCLC tumor cell expression that is c-Met+ per central lab immunohistochemistry (IHC) assay specification, who have previously progressed on systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible) and prior anti-cancer therapies targeting driver gene alterations (if applicable) and who have received no more than 2 lines of prior systemic chemotherapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the metastatic setting.

Where’s this trial being run?

St Vincents University Hospital and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: AbbVie M14-239
Number: 18-49
Full Title:

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Principal Investigator: Dr Emer Hanrahan (St. Vincent's University Hospital)
Type: Industry Sponsored


Recruitment Started: Global: October 2018
Ireland: November 2019- Closing 30-Jun-2023
Global Recruitment Target: 270
Ireland Recruitment Target: 9